Skip to content
10-Q

Quarterly Report

OnKure Therapeutics, Inc. OKUR

0001193125-26-206345

← back to feed
Filed
May 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 4, 2026 40.4M sh
Shares Diluted Q1 2026 · Mar 31, 2026 13.67M sh
Shares Diluted Q1 2026 · Mar 31, 2025 13.42M sh
Capex Q1 2026 · Mar 31, 2026 $5K
Capex Q1 2026 · Mar 31, 2025 $18K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$12.94M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$14.01M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $192.11M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $59.05M
Stockholders Equity Q1 2026 · Mar 31, 2026 $184.35M
Stockholders Equity Q1 2026 · Dec 31, 2025 $56.18M
Stockholders Equity Q1 2026 · Sep 30, 2025 $66.43M
Stockholders Equity Q1 2026 · Jun 30, 2025 $78.17M
Stockholders Equity Q1 2026 · Mar 31, 2025 $90.65M
Stockholders Equity Q1 2026 · Dec 31, 2024 $103.83M
Current Liabilities Q1 2026 · Mar 31, 2026 $14.33M
Current Liabilities Q1 2026 · Dec 31, 2025 $5.92M
Total Liabilities Q1 2026 · Mar 31, 2026 $14.34M
Total Liabilities Q1 2026 · Dec 31, 2025 $5.93M
Current Assets Q1 2026 · Mar 31, 2026 $197.48M
Current Assets Q1 2026 · Dec 31, 2025 $60.84M
Total Assets Q1 2026 · Mar 31, 2026 $198.69M
Total Assets Q1 2026 · Dec 31, 2025 $62.12M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.11
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.19
Eps Basic Q1 2026 · Mar 31, 2026 −$1.11
Eps Basic Q1 2026 · Mar 31, 2025 −$1.19
Sga Expense Q1 2026 · Mar 31, 2026 $3.91M
Sga Expense Q1 2026 · Mar 31, 2025 $3.99M
Rd Expense Q1 2026 · Mar 31, 2026 $11.71M
Rd Expense Q1 2026 · Mar 31, 2025 $13.01M
Net Income Q1 2026 · Mar 31, 2026 −$15.16M
Net Income Q1 2026 · Dec 31, 2025 −$13.5M
Net Income Q1 2026 · Sep 30, 2025 −$14.7M
Net Income Q1 2026 · Jun 30, 2025 −$15.39M
Net Income Q1 2026 · Mar 31, 2025 −$15.93M
Operating Income Q1 2026 · Mar 31, 2026 −$15.62M
Operating Income Q1 2026 · Mar 31, 2025 −$17M